Author/Authors :
Jaberi, Nayyer Research Center of Psychiatry and Behavioral Sciences - Tabriz University of Medical sciences, Tabriz, Iran , Faramarzi, Elnaz Liver and Gastrointestinal Diseases Research center - Tabriz University of Medical sciences, Tabriz, Iran , Farahbakhsh, Mostafa Research Center of Psychiatry and Behavioral Sciences - Tabriz University of Medical sciences, Tabriz, Iran , Ostadarahimi, Alireza Nutrition Research Center - Tabriz University of medical sciences, Tabriz, Iran , Asghari Jafarabadi, Mohammad Medical Education Research Center - Department of Statistics and Epidemiology, Faculty of Health - Tabriz University of Medical Sciences, Tabriz, Iran , Fakhari, Ali Research Center of Psychiatry and Behavioral Sciences - Tabriz University of Medical sciences, Tabriz, Iran
Abstract :
This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications.
Methods: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatment with antipsychotic medications, fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL), weight, waist circumference (WC), and blood pressure were determined. We defined Mets according to ATPIII criteria.
Results: After a 6-month treatment with antipsychotic drugs, the mean WC, serum TG, HDL, systolic and diastolic blood pressure increased but the changes of WC and HDL were statistically significant (p<0.05). We found that the percentage of patients with high WC, low HDL levels, and Mets increased after treatment which was statistically significant (p<0.05).
Conclusion: It is recommended that nutritional and lifestyle changes intervention should be implanted for schizophrenic patients undergoing treatment.
